Published in Curr Top Cell Regul on January 01, 1979
Tumor cell autocrine motility factor. Proc Natl Acad Sci U S A (1986) 2.28
Migration by haptotaxis of a Schwann cell tumor line to the basement membrane glycoprotein laminin. J Cell Biol (1983) 2.07
Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils. J Exp Med (1982) 2.04
Laminin and fibronectin promote the haptotactic migration of B16 mouse melanoma cells in vitro. J Cell Biol (1984) 1.95
Human endothelial cells are chemotactic to endothelial cell growth factor and heparin. J Cell Biol (1985) 1.56
Novel neutrophil chemotactic factor derived from human peripheral blood mononuclear leucocytes. Clin Exp Immunol (1986) 1.40
Stimulation of tubulin tyrosinolation in rabbit leukocytes evoked by the chemoattractant formyl-methionyl-leucyl-phenylalanine. J Cell Biol (1981) 1.02
Functional homology of chemotactic methylesterases from Bacillus subtilis and Escherichia coli. J Bacteriol (1989) 0.91
Interactions of cytoplasmic granules with microtubules in human neutrophils. J Cell Biol (1989) 0.85
Control of cellular influx in lung and its role in pulmonary toxicology. Environ Health Perspect (1984) 0.82
The effect of a sulfonated shale oil extract (Ichthyol) on the migration of human neutrophilic granulocytes in vitro. Arch Dermatol Res (1984) 0.81
Inhibitory effect of sulfonated shale oils (ammonium bituminosulfonate) on the stimulation of neutrophilic granulocytes by the chemotactic tripeptide f-Met-Leu-Phe. Arch Dermatol Res (1986) 0.75
Chemotaxis: basic aspects of methodology, mechanisms and pathology. Arch Dermatol Res (1983) 0.75
N-formylmethionyl peptides as chemoattractants for leucocytes. Proc Natl Acad Sci U S A (1975) 9.24
The structure-activity relations of synthetic peptides as chemotactic factors and inducers of lysosomal secretion for neutrophils. J Exp Med (1976) 7.57
Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) (2000) 7.17
Hyper-IgE syndrome with recurrent infections--an autosomal dominant multisystem disorder. N Engl J Med (1999) 5.82
Granulocyte chemotaxis: an improved in vitro assay employing 51 Cr-labeled granulocytes. J Immunol (1973) 4.61
A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acad Sci U S A (1980) 4.45
Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) (2000) 4.45
The p47phox mouse knock-out model of chronic granulomatous disease. J Exp Med (1995) 4.25
The regulatory role of divalent cations in human granulocyte chemotaxis. Evidence for an association between calcium exchanges and microtubule assembly. J Cell Biol (1974) 4.10
Platelet-derived growth factor in chemotactic for fibroblasts. J Cell Biol (1982) 4.08
Demonstration of a receptor on rabbit neutrophils for chemotactic peptides. Biochem Biophys Res Commun (1977) 3.81
The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J Immunol (1975) 3.50
Structural analysis of human neutrophil migration. Centriole, microtubule, and microfilament orientation and function during chemotaxis. J Cell Biol (1977) 3.33
Current concepts: immunology. Neutrophils in human diseases. N Engl J Med (1987) 3.29
Cloning of a 67-kD neutrophil oxidase factor with similarity to a noncatalytic region of p60c-src. Science (1990) 3.15
Evidence for distinct intracellular pools of receptors for C3b and C3bi in human neutrophils. J Immunol (1985) 3.02
Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem (1992) 2.93
Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med (2001) 2.75
Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet (1999) 2.63
Chemoattractants stimulate degradation of methylated phospholipids and release of arachidonic acid in rabbit leukocytes. Proc Natl Acad Sci U S A (1979) 2.62
Role of secretory events in modulating human neutrophil chemotaxis. J Clin Invest (1978) 2.59
Kinetic analysis of chemotactic factor generation in human serum via activation of the classical and alternate complement pathways. Clin Immunol Immunopathol (1975) 2.56
Burkholderia pseudomallei infection in a Puerto Rican patient with chronic granulomatous disease: case report and review of occurrences in the Americas. Clin Infect Dis (1998) 2.53
Human leukocytic pyrogen induces release of specific granule contents from human neutrophils. J Clin Invest (1978) 2.48
The selective eosinophil chemotactic activity of histamine. J Exp Med (1975) 2.45
Interaction of leukocyte chemotactic factors with the cell surface. I. Chemotactic factor-induced changes in human granulocyte surface charge. J Clin Invest (1975) 2.40
Recombinant 47-kilodalton cytosol factor restores NADPH oxidase in chronic granulomatous disease. Science (1989) 2.39
Role of a peptidase in phagocyte chemotaxis. Proc Natl Acad Sci U S A (1976) 2.38
Histamine type I receptor occupancy increases endothelial cytosolic calcium, reduces F-actin, and promotes albumin diffusion across cultured endothelial monolayers. J Cell Biol (1986) 2.36
Chemotactic cytokines: the role of leukocytic pyrogen and epidermal cell thymocyte-activating factor in neutrophil chemotaxis. J Immunol (1984) 2.34
An inherited abnormality of neutrophil adhesion. Its genetic transmission and its association with a missing protein. N Engl J Med (1980) 2.32
Tumor cell autocrine motility factor. Proc Natl Acad Sci U S A (1986) 2.28
Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med (2000) 2.26
Mechanism for the inflammatory response in primate lungs. Demonstration and partial characterization of an alveolar macrophage-derived chemotactic factor with preferential activity for polymorphonuclear leukocytes. J Clin Invest (1977) 2.24
Secretory responses of human neutrophils: exocytosis of specific (secondary) granules by human neutrophils during adherence in vitro and during exudation in vivo. J Immunol (1979) 2.20
Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med (1994) 2.07
Granulocyte function in the Chediak-Higashi syndrome of mice. Blood (1974) 2.04
Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) (1998) 2.03
Two forms of autosomal chronic granulomatous disease lack distinct neutrophil cytosol factors. Science (1988) 2.00
Use of lipophilic probes of membrane potential to assess human neutrophil activation. Abnormality in chronic granulomatous disease. J Clin Invest (1980) 1.97
Immunologic reactivity of the lung: the in vivo and in vitro generation of a neutrophil chemotactic factor by alveolar macrophages. Am Rev Respir Dis (1978) 1.97
IL-4 inhibits superoxide production by human mononuclear phagocytes. J Immunol (1990) 1.94
Genetic variants of chronic granulomatous disease: prevalence of deficiencies of two cytosolic components of the NADPH oxidase system. N Engl J Med (1989) 1.93
Serum lipids in infection. N Engl J Med (1969) 1.93
Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells. J Cell Biol (1990) 1.89
Stimulation of neutrophil oxygen-dependent metabolism by human leukocytic pyrogen. J Clin Invest (1979) 1.85
Successful treatment of Paecilomyces varioti infection in a patient with chronic granulomatous disease and a review of Paecilomyces species infections. Clin Infect Dis (1992) 1.84
Separation and functional characterization of human neutrophil subpopulations. Blood (1978) 1.80
Role of attachment factors and attractants in fibroblast chemotaxis. J Lab Clin Med (1980) 1.80
Raipid stimulation of protein carboxymethylation in leukocytes by a chemotatic peptide. Nature (1978) 1.77
NIH conference. Recent advances in chronic granulomatous disease. Ann Intern Med (1983) 1.76
Degranulating stimuli increase the availability of receptors on human neutrophils for the chemoattractant f-met-leu-phe. J Immunol (1980) 1.74
Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res (2001) 1.73
Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. J Clin Invest (1974) 1.69
Interaction of chemotactic factors with human macrophages. Induction of transmembrane potential changes. J Cell Biol (1977) 1.64
Microbicidal/cytotoxic proteins of neutrophils are deficient in two disorders: Chediak-Higashi syndrome and "specific" granule deficiency. J Clin Invest (1988) 1.63
Severe Burkholderia (Pseudomonas) gladioli infection in chronic granulomatous disease: report of two successfully treated cases. Clin Infect Dis (1995) 1.63
Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response. Blood (1982) 1.62
Interaction of chemotactic factors with human polymorphonuclear leukocytes: studies using a membrane potential-sensitive cyanine dye. J Membr Biol (1980) 1.62
The differential mobilization of human neutrophil granules. Effects of phorbol myristate acetate and ionophore A23187. Am J Pathol (1977) 1.60
Correlation of human neutrophil secretion, chemoattractant receptor mobilization, and enhanced functional capacity. J Immunol (1982) 1.58
Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect Dis (1990) 1.55
Spleen-derived mononuclear cell chemotactic factor in malaria infections: a possible mechanism for splenic macrophage accumulation. J Immunol (1977) 1.53
Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis (1990) 1.49
Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A (1997) 1.48
A functional differentiation of human neutrophil granules: generation of C5a by a specific (secondary) granule product and inactivation of C5a by azurophil (primary) granule products. J Immunol (1977) 1.47
Presence of autoantibody for phospholipase inhibitory protein, lipomodulin, in patients with rheumatic diseases. Proc Natl Acad Sci U S A (1981) 1.47
The relationship between alloimmunization and posttransfusion granulocyte survival: experience in a chronic granulomatous disease cohort. Transfusion (2010) 1.45
The cell binding fragment of fibronectin is chemotactic for fibroblasts. Cell Biol Int Rep (1981) 1.45
Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/enhancer binding protein epsilon. J Exp Med (1999) 1.44
Human immunodeficiency virus (HIV) infection in CD4+ T lymphocytes genetically deficient in LFA-1: LFA-1 is required for HIV-mediated cell fusion but not for viral transmission. J Exp Med (1991) 1.44
Exudation primes human and guinea pig neutrophils for subsequent responsiveness to the chemotactic peptide N-formylmethionylleucylphenylalanine and increases complement component C3bi receptor expression. J Clin Invest (1986) 1.41
Degranulating stimuli decrease the neagative surface charge and increase the adhesiveness of human neutrophils. J Clin Invest (1980) 1.41
Use of an X-linked human neutrophil marker to estimate timing of lyonization and size of the dividing stem cell pool. J Clin Invest (1985) 1.41
Further studies on the structural requirements for synthetic peptide chemoattractants. Biochemistry (1980) 1.40
Impairment of neutrophil bactericidal capacity in patients with AIDS. J Infect Dis (1988) 1.38
Evidence for a functional cytoplasmic domain of phagocyte oxidase cytochrome b558. J Biol Chem (1990) 1.38
Effect of prophylactic colchicine therapy on leukocyte function in patients with familial Mediterranean fever. Arthritis Rheum (1976) 1.36
Human neutrophil heterogeneity exists, but is it meaningful? Blood (1984) 1.35
Immunochemical evidence for a novel pertussis toxin substrate in human neutrophils. J Biol Chem (1986) 1.33
Deactivation of human neutrophil chemotaxis by chemoattractants: effect on receptors for the chemotactic factor f-Met-Leu-Phe. J Immunol (1981) 1.33
Human neutrophils contain an intracellular pool of putative receptors for the chemoattractant N-formyl-methionyl-leucyl-phenylalanine. Blood (1983) 1.32
The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells. J Biol Chem (1989) 1.31
Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. Proc Natl Acad Sci U S A (1988) 1.31
Adult tissues contain chemoattractants for vascular endothelial cells. Nature (1980) 1.30
Agents that increase cyclic AMP inhibit accumulation of cGMP and depress human monocyte locomotion. J Immunol (1978) 1.29
The hyperimmunoglobulin E recurrent-infection (Job's) syndrome. A review of the NIH experience and the literature. Medicine (Baltimore) (1983) 1.28
Leucocyte chemotaxis: physiological considerations and abnormalities. Clin Haematol (1975) 1.28
Adaptation of human neutrophil responsiveness to the chemoattractant N-formylmethionylleucylphenylalanine. Heterogeneity and/or negative cooperative interaction of receptors. J Biol Chem (1982) 1.28
Chemotactic activity in dialyzable transfer factor. Proc Natl Acad Sci U S A (1974) 1.26
Human neutrophil heterogeneity identified using flow microfluorometry to monitor membrane potential. J Clin Invest (1981) 1.26
Oxidative killing of Aspergillus fumigatus proceeds by parallel myeloperoxidase-dependent and -independent pathways. Infect Immun (1987) 1.26
Endotoxin and IL-1 hyporesponsiveness in a patient with recurrent bacterial infections. J Immunol (1997) 1.26
Abnormal regulation of inflammatory skin responses in male patients with chronic granulomatous disease. Inflammation (1983) 1.25
Effects of serotonin, carbamylcholine, and ascorbic acid on leukocyte cyclic GMP and chemotaxis. J Cell Biol (1975) 1.24
Effects of levamisole on normal and abnormal leukocyte locomotion. J Clin Invest (1977) 1.23
Enzymatic reduction of oxidized chemotactic peptide N-formyl-L-methionyl-sulfoxide-L-leucyl-L-phenylalanine. Biochem Biophys Res Commun (1982) 1.23
Mononuclear cell chemotactic activity of kallikrein and plasminogen activator and its inhibition by C1 inhibitor and alpha 2-macroglobulin. J Immunol (1974) 1.22
Glycolysis as primary energy source in tumor cell chemotaxis. J Natl Cancer Inst (1990) 1.21